The European Commission announced the approval of Truvada as PrEP (pre-exposure prophylaxis for HIV) in all 28 EU member states, last week (Monday 22nd). Experts believe that it will be available on the pharmaceutical market within the next 6 months. Already now PrEP plays an important role, along with other measures, in HIV prevention.
PrEP stands for Pre-Exposure Prophylaxis. PrEP is a way for people who don’t have HIV but who are at very high risk of getting it to prevent HIV infection by taking a pill every day. The pill contains two medicines that are also used to treat HIV.
At the International AIDS Conference 2016 in Durban, where AIDS Action Europe also participated, first successes in the use of PrEP were reported. In particular, after its introduction, the incidence rate decreased among MSM in San Francisco (USA) and in New South Wales (Australia).
PrEP has a relatively high price, and therefore, without health insurance reimbursement, is affordable to very few people. It is hoped that in the future more options for PrEP will be available, and generic products will also enter the market that would dramatically reduce the costs of this highly effective HIV-prevention method.